What are your top takeaways in GI Cancers from ASCO 2022?

1. DYNAMIC study: I believe circulating tumor DNA (ctDNA) will dramatically improve personalized medicine for cancer patients. This study confirmed that ctDNA-based adjuvant chemo treatment significantly decreases the patients who need/are recommended for adjuvant treatment (50% reduction) without c...

1. Dostarlimab in MSI-high locally advanced rectal cancer: Small n=12 but 100% clinical complete response to single-agent anti-PD1 obviated the need for chemoradiation or surgery. Potentially huge implications for both sporadic and germline dMMR rectal Ca!

2. DYNAMIC ctDNA guidance of adjuvant therap...

1. First pick is not surprising! Dostarlimab's success in MSI-h rectal cancer study demonstrated a remarkable response rate in locally advanced rectal cancer. Longer term follow-up is certainly needed but what is notable is the contrast in response rate for earlier stage vs late stage disease.
2. DYNAMI...

1. Poster 2516, Balachandran et al. - phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine for pancreatic ductal adenocarcinoma – in the group that got the vaccine with a response no recurrences out to 18 months of follow up (nearly all of the non-responders have rel...